Menactra vaccine adults

<альтернативный текст

July 8, 2019
menactra vaccine adults

В  in certain situations, cdc also recommends other children and adults get a meningococcal vaccine. Below is more information about which meningococcal vaccines cdc recommends for people by age. Talk to your or your childs clinician about what is best for your specific situation.

В  adolescents and young adults (16 through 23 years of age) may also receive a menb vaccine. The preferred age at which to administer a menb vaccine is 16 through 18 years. Cdc recommends that certain adolescents and young adults should receive a menb vaccine.

Some adults may need another type of meningitis vaccine, the serogroup b meningococcal vaccine, if they are exposed to this virus through work or travel or if they have a damaged or missing spleen.

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, y, and w-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent n meningitidis serogroup b disease.

Menactra is for use in children and adults between the ages of 9 months and 55 years old. Like any vaccine, menactra may not provide protection from disease in every person.

Menactra is a meningococcal conjugate vaccine to protect against meningococcal groups a, c, y and w. The vaccine is funded for children and adults with a medical condition that increases their risk of invasive meningococcal disease and is listed on the pharmaceutical schedule.

When menactra and daptacel (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) are to be administered to children 4 through 6 years of age, preference should be given.

В  detailed meningococcal conjugate vaccine dosage information for adults and children. Includes dosages for meningococcal meningitis prophylaxis plus renal, liver and dialysis adjustments.

We are building this new website to better deliver information. We are building this new website to better deliver information.